Overview

SS-31, also known as elamipretide, Bendavia, or MTP-131, is a synthetic aromatic-cationic tetrapeptide developed to selectively target the inner mitochondrial membrane. Unlike many peptide therapeutics that act primarily through extracellular receptors, SS-31 enters cells and accumulates near cardiolipin-rich regions of the inner mitochondrial membrane, where it has been studied for effects on mitochondrial structure, oxidative phosphorylation, ATP production, and stress resilience.

Cardiolipin is a specialized phospholipid located primarily within the inner mitochondrial membrane. It supports cristae architecture, respiratory-chain organization, ATP synthase activity, and efficient electron transport. Oxidative modification or abnormal remodeling of cardiolipin has been implicated in mitochondrial dysfunction associated with aging, ischemia-reperfusion injury, heart failure, kidney injury, retinal disease, skeletal-muscle dysfunction, and inherited mitochondrial disorders.

Experimental investigations suggest that SS-31 interacts with cardiolipin and may help preserve mitochondrial membrane organization during cellular stress. Rather than acting as a conventional antioxidant that directly neutralizes free radicals, SS-31 is generally described as a mitochondrial membrane stabilizer that may reduce secondary oxidative stress by improving electron-transport efficiency and reducing electron leak.

Quick Reference

Discovery and Development

SS-31 was developed during research programs aimed at identifying small peptides capable of localizing to mitochondria and protecting mitochondrial function during oxidative and energetic stress. Researchers designed aromatic-cationic peptides with alternating charged and aromatic residues, a structure that supports cellular entry and association with mitochondrial membranes.

Among the Szeto-Schiller peptide family, SS-31 emerged as one of the most extensively studied candidates because of its mitochondrial localization, favorable experimental handling properties, and reproducible effects across several models of mitochondrial injury.

Over time, SS-31 advanced from cellular bioenergetics research into animal models and then into human clinical development programs. This makes SS-31 distinct from many research peptides whose evidence base remains almost entirely preclinical.

Molecular Structure

SS-31 is a synthetic tetrapeptide with alternating aromatic and cationic residues. Its commonly reported sequence is D-Arg-2′,6′-dimethylTyr-Lys-Phe-NH₂. The peptide’s small size, charge distribution, and aromatic residues support cellular penetration and association with mitochondrial membranes.

Unlike larger peptide hormones that depend on receptor binding at the cell surface, SS-31 can enter cells and localize near mitochondrial membranes. This feature is central to its research identity as a mitochondria-targeting peptide.

Cardiolipin Biology and Mitochondrial Membrane Architecture

The biological activity of SS-31 is closely linked to cardiolipin, a phospholipid concentrated within the inner mitochondrial membrane. Cardiolipin is essential for cristae curvature, respiratory-chain supercomplex organization, electron transport, and ATP synthase function.

The inner mitochondrial membrane

The inner mitochondrial membrane houses electron transport chain complexes I through IV and ATP synthase, also known as complex V. Its folded cristae architecture dramatically expands membrane surface area and creates specialized microdomains for oxidative phosphorylation. Disruption of cristae structure impairs respiratory efficiency and increases susceptibility to energetic failure.

Cardiolipin functions

• Maintains mitochondrial cristae architecture.
• Stabilizes respiratory-chain complexes and supercomplexes.
• Supports ATP synthase organization.
• Anchors mitochondrial proteins.
• Regulates membrane curvature and mitochondrial dynamics.

Cardiolipin is vulnerable to oxidative modification because it is located near respiratory-chain sites that generate reactive oxygen species. Oxidized cardiolipin has been associated experimentally with cristae disruption, impaired oxidative phosphorylation, cytochrome c release, mitochondrial fragmentation, and activation of cell-death pathways.

SS-31 and cardiolipin

Mechanistic studies indicate that SS-31 associates with cardiolipin-rich regions of the inner mitochondrial membrane. This interaction is believed to preserve cardiolipin-protein interactions, stabilize respiratory-chain organization, and reduce secondary oxidative injury during cellular stress.

Mechanism and Cellular Signaling

Mitochondrial membrane stabilization

SS-31 is best understood as a mitochondrial membrane stabilizer rather than a conventional receptor agonist. Experimental studies have reported preservation of cristae organization, reduction of mitochondrial swelling, improved membrane continuity, and better maintenance of respiratory-chain architecture following SS-31 exposure in models of metabolic or ischemic stress.

Oxidative phosphorylation

Oxidative phosphorylation couples electron transport to ATP synthesis through establishment of a proton gradient across the inner mitochondrial membrane. When membrane organization is disrupted, oxidative phosphorylation becomes less efficient. SS-31 has been associated with improved basal respiration, maximal respiratory capacity, ATP-linked oxygen consumption, and coupling efficiency in experimental systems.

Reactive oxygen species modulation

Reactive oxygen species serve normal signaling functions but become damaging when produced excessively. Rather than directly scavenging radicals as a simple antioxidant, SS-31 appears to reduce oxidative stress indirectly by improving electron-transport efficiency and reducing electron leak. Experimental studies have reported reductions in lipid peroxidation, oxidative protein modification, and mitochondrial oxidative-stress markers.

Mitochondrial permeability transition pore

Opening of the mitochondrial permeability transition pore can collapse membrane potential, deplete ATP, and initiate cell-death signaling. Preclinical research suggests that SS-31 may reduce susceptibility to pathological pore opening during severe mitochondrial stress.

Apoptosis and cytochrome c

By preserving mitochondrial membrane integrity, SS-31 may help retain cytochrome c within mitochondria and reduce activation of downstream apoptotic pathways. This mechanism has been investigated in ischemia-reperfusion, renal injury, cardiac injury, and neurodegenerative models.

Cardiovascular Research

Cardiovascular disease has been one of the principal areas of SS-31 investigation because the heart is among the most mitochondria-rich organs in the body. Under normal physiological conditions, cardiac muscle derives most of its ATP through oxidative phosphorylation. Even modest impairments in mitochondrial function may reduce myocardial efficiency, compromise contractility, and increase susceptibility to ischemic injury.

Ischemia-reperfusion injury

Myocardial ischemia occurs when coronary blood flow becomes insufficient to meet metabolic demand. Restoration of blood flow is essential, but reperfusion itself may initiate oxidative stress, calcium overload, mitochondrial dysfunction, inflammation, and mitochondrial permeability transition pore opening.

Animal studies evaluating SS-31 during ischemia-reperfusion have reported reduced infarct size, preservation of mitochondrial ultrastructure, improved ATP production, reduced mitochondrial swelling, lower oxidative-stress markers, and improved ventricular performance. These findings support the concept that mitochondrial membrane stabilization can influence secondary injury pathways after ischemic stress.

Heart failure and cardiac bioenergetics

Heart failure is increasingly recognized as a disorder involving impaired mitochondrial function in addition to structural remodeling. Experimental models have demonstrated reduced mitochondrial respiration, increased oxidative damage, loss of cristae organization, impaired ATP generation, and progressive ventricular dysfunction.

Preclinical SS-31 studies have reported improved left ventricular function, better mitochondrial organization, reduced oxidative injury, enhanced exercise capacity, and preservation of cardiac bioenergetics. Human studies have produced more variable results, with some improvements in selected physiological or biomarker endpoints while other trials did not meet all predefined efficacy endpoints.

Renal Research and Acute Kidney Injury

The kidney contains a high density of mitochondria, particularly within proximal tubular epithelial cells. Continuous ATP production is required to maintain ion transport, glomerular filtration, tubular reabsorption, and acid-base homeostasis. Mitochondrial dysfunction is therefore central to acute kidney injury, chronic kidney disease, diabetic kidney disease, and renal ischemia-reperfusion injury.

Acute kidney injury

Animal studies evaluating SS-31 in acute kidney injury models have reported preservation of mitochondrial ultrastructure, reduced tubular epithelial injury, improved ATP production, lower oxidative stress, reduced inflammatory infiltration, and improved renal histology. These findings are consistent with a mechanism based on stabilization of cardiolipin and preservation of oxidative phosphorylation.

Renal ischemia-reperfusion

Experimental renal ischemia-reperfusion models have reported reduced mitochondrial swelling, preservation of cristae architecture, improved oxygen utilization, reduced reactive oxygen species production, improved renal perfusion, and lower histological injury scores following SS-31 exposure.

Diabetic and chronic kidney disease models

Diabetic nephropathy and chronic kidney disease involve progressive mitochondrial dysfunction, oxidative stress, endothelial injury, inflammation, and fibrotic remodeling. Experimental SS-31 studies have reported improved mitochondrial respiration, reduced oxidative injury, better preservation of renal ultrastructure, improved tubular function, and reduced fibrotic remodeling in selected models. Human renal evidence remains more limited than the preclinical literature.

Skeletal Muscle, Exercise Physiology, and Aging Research

Skeletal muscle depends on a large mitochondrial network to generate ATP for contraction, calcium handling, and recovery. Age-associated declines in mitochondrial function have been implicated in reductions in muscle strength, endurance, exercise capacity, and physical performance.

Skeletal-muscle bioenergetics

Laboratory investigations have reported improved mitochondrial respiration after SS-31 exposure, including increased oxidative phosphorylation, better ATP generation, improved coupling efficiency, reduced proton leak, increased maximal respiratory capacity, and improved mitochondrial reserve capacity.

Exercise capacity and fatigue resistance

Animal studies have reported increased treadmill endurance, delayed fatigue, improved exercise tolerance, better post-exercise recovery, and preservation of mitochondrial respiration following strenuous exercise. These findings suggest improved mitochondrial efficiency rather than direct stimulation of muscle hypertrophy.

Aging biology

Normal aging is associated with reduced ATP synthesis, increased oxidative stress, cristae disorganization, reduced respiratory efficiency, decreased mitochondrial density, and accumulation of mitochondrial DNA damage. SS-31 has been studied in aging models for its potential to preserve mitochondrial architecture and improve energetic efficiency.

Neurological, Ophthalmologic, and Mitochondrial Disease Research

The nervous system and retina have high energy demands and depend heavily on mitochondrial ATP production. Mitochondrial dysfunction has been implicated in neurodegenerative disease, optic neuropathies, inherited mitochondrial disorders, and retinal degeneration.

Neurological models

Experimental studies in neurological models have reported preservation of mitochondrial morphology, improved ATP production, reduced oxidative stress, better neuronal survival, improved mitochondrial respiration, and reduced accumulation of damaged mitochondria. These observations support continued investigation but do not establish clinical efficacy.

Retinal and ophthalmologic research

The retina contains one of the highest mitochondrial densities in the body. Photoreceptors and retinal pigment epithelial cells require continuous ATP production to sustain visual function. SS-31 has been investigated in dry age-related macular degeneration and related retinal disorders, with studies evaluating visual function, low-luminance performance, reading outcomes, retinal imaging, and safety.

Primary mitochondrial disease

Inherited mitochondrial disorders result from pathogenic variants affecting oxidative phosphorylation. Clinical manifestations may include muscle weakness, exercise intolerance, neurological dysfunction, cardiomyopathy, vision impairment, and multi-organ involvement. SS-31 has been evaluated in clinical programs involving primary mitochondrial myopathy and Barth syndrome, where cardiolipin biology is particularly relevant.

Human Clinical Research

SS-31 has one of the most mature clinical development histories among mitochondria-targeting peptides. Human studies have evaluated safety, pharmacokinetics, functional outcomes, visual outcomes, biomarkers, and disease-specific endpoints across multiple indications.

Clinical development has included studies in primary mitochondrial disease, Barth syndrome, heart failure, renal disease, dry age-related macular degeneration, and skeletal-muscle dysfunction. Results have varied by indication, patient population, endpoint selection, and trial duration. Some studies reported improvements in selected functional or patient-reported measures, while others did not achieve all predefined primary endpoints.

Safety and Translational Considerations

Across completed clinical investigations, SS-31 has generally demonstrated a favorable tolerability profile within studied populations, with injection-site reactions among commonly discussed adverse events in approved or clinical contexts. Long-term safety, disease-specific risks, drug interactions, and use in special populations require interpretation within formal clinical and regulatory frameworks.

Translation from improved mitochondrial function to measurable clinical benefit is complex. Improved respiration, ATP production, or oxidative-stress markers do not always produce consistent functional improvement across heterogeneous diseases. Patient selection, disease stage, trial duration, endpoint design, and biomarker validation are all critical considerations.

Analytical Testing

HPLC purity

High-performance liquid chromatography is commonly used to estimate peptide purity. A chromatogram separates detected components under defined method conditions. The main peak represents the dominant detected component, while smaller peaks may represent related impurities, incomplete sequences, oxidation products, synthesis byproducts, or degradation products.

Mass confirmation

Mass spectrometry, including LC-MS or MALDI-based methods, may be used to compare observed molecular mass with the expected mass of SS-31. Mass confirmation helps support identity but does not by itself prove purity, biological activity, sterility, or suitability for any specific experimental system.

COA interpretation

A batch-specific Certificate of Analysis should identify the compound name, lot number, analytical method, purity result, identity-confirmation method when available, appearance, and testing date. COA documentation supports traceability but does not replace internal laboratory validation.

Purity Standards and Research Documentation

For laboratory research, documentation should be clear, lot-specific, and traceable. Researchers commonly review HPLC purity, mass confirmation, visual appearance, storage history, and reconstitution records. Internal laboratory notebooks should record date received, date opened, storage conditions, solvent system, concentration, aliquoting procedure, freeze-thaw history, and any deviations from standard procedure.

Because SS-31 is studied in sensitive bioenergetic systems, experimental reproducibility depends on both compound quality and method consistency. Variability in solvent, concentration, pH, storage time, cell type, mitochondrial stress model, and assay timing may alter results.

Stability and Laboratory Handling

Research peptides are commonly supplied as lyophilized powders because reduced water content can improve storage stability. Peptide integrity may still be affected by temperature, moisture, oxygen exposure, light, pH, concentration, and repeated freeze-thaw cycling.

General laboratory handling principles include minimizing moisture exposure, using clean technique, protecting material from unnecessary heat and light, avoiding repeated freeze-thaw cycles when possible, keeping clear batch records, and following validated internal procedures for preparation and storage.

Once a peptide is dissolved, stability may differ from lyophilized stability. Solution-phase peptides can be more vulnerable to hydrolysis, oxidation, adsorption to container surfaces, microbial contamination, and concentration-dependent degradation. Research groups should validate storage and handling conditions for their specific assay system.

Frequently Asked Questions

What is SS-31?

SS-31, also known as elamipretide, is a synthetic aromatic-cationic tetrapeptide studied for mitochondrial targeting, cardiolipin interaction, mitochondrial membrane stabilization, oxidative phosphorylation, and cellular bioenergetics.

Is SS-31 the same as elamipretide?

Yes. SS-31 is the research name commonly associated with elamipretide, also historically referenced as Bendavia or MTP-131 in scientific and clinical-development literature.

What is cardiolipin?

Cardiolipin is a specialized phospholipid concentrated within the inner mitochondrial membrane. It helps maintain cristae structure, respiratory-chain organization, ATP synthase function, and efficient electron transport.

Does SS-31 work like a traditional antioxidant?

Not exactly. SS-31 is better described as a mitochondrial membrane stabilizer. It may reduce oxidative stress indirectly by improving electron-transport efficiency and reducing electron leak rather than simply scavenging free radicals.

Has SS-31 been studied in humans?

Yes. SS-31 has been studied in multiple human clinical programs involving mitochondrial disease, Barth syndrome, heart failure, renal disease, ophthalmologic disease, and skeletal-muscle dysfunction.

Is SS-31 FDA approved?

Forzinity, an elamipretide injection, received U.S. FDA accelerated approval for Barth syndrome in patients weighing at least 30 kg. This page does not present SS-31 for any broader human or veterinary use.

What analytical testing is relevant for SS-31?

Common research documentation may include HPLC purity analysis, mass spectrometry identity confirmation, batch-specific COA information, appearance, lot traceability, and storage documentation.

Is this medical advice?

No. This page is educational content for laboratory research contexts only and does not provide medical advice, dosing guidance, treatment recommendations, or administration instructions.

References and Further Reading

• Szeto HH. Mitochondria-targeted peptide antioxidants: novel neuroprotective agents. AAPS Journal. 2006.
• Zhao K et al. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. Journal of Biological Chemistry. 2004.
• Birk AV et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. Journal of the American Society of Nephrology. 2013.
• Dai DF et al. Mitochondrial targeted antioxidant peptide ameliorates hypertensive cardiomyopathy. Journal of the American College of Cardiology. 2011.
• Siegel MP et al. Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice. Aging Cell. 2013.
• Szeto HH and Birk AV. Serendipity and the discovery of novel compounds that restore mitochondrial plasticity. Clinical Pharmacology & Therapeutics. 2014.
• Stealth BioTherapeutics clinical development publications and trial records involving elamipretide in mitochondrial disease, heart failure, retinal disease, renal disease, and Barth syndrome.
• U.S. Food and Drug Administration. FDA grants accelerated approval to Forzinity (elamipretide) injection for Barth syndrome. 2025.
• ClinicalTrials.gov. Elamipretide investigational trial records.